Celltrion Wins Peru Tenders for Adalimumab, Trastuzumab & Rituximab Biosimilars

On 19 February 2024, the Korea Biomedical Review published that Celltrion secured a series of tenders to supply biosimilars in Peru including relating to Herzuma® (trastuzumab biosimilar),  Truxima® (rituximab biosimilar) and Yulfyma® (adalimumab).  These contracts effectively secure more than 50% of the Peruvian rituximab and trastuzumab markets, and an estimated 20% of the Peruvian adalimumab market.